Imatinib remains the best frontline therapy in patients with chronic myeloid leukemia: Critical analysis of the <scp>ASC4FIRST</scp> trial

Authors:

Published: 0000-00-00

DOI: HTTPS://DOI.ORG/10.1002/ajh.27477

Keywords:

Abstract:

Source: